These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36269138)

  • 21. Seroprevalence of SARS-CoV-2 in healthcare workers from outpatient facilities and retirement or nursing homes in a Swiss canton.
    Zürcher K; Mugglin C; Suter-Riniker F; Keller PM; Egger M; Müller S; Fluri M; Hoffmann M; Fenner L
    Swiss Med Wkly; 2021 Aug; 151():w30021. PubMed ID: 34495604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among unvaccinated children of Chandigarh, Northwest India, in a household-based paediatric serosurvey post-second wave of pandemic (June to July 2021).
    Ghosh A; Goyal K; Singh R; Lakshmi PVM; Kaur R; Kumar V; Muralidharan J; Puri GD; Ram J; Singh MP
    Public Health; 2023 Dec; 225():160-167. PubMed ID: 37931485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.
    Bryan A; Tatem K; Diuguid-Gerber J; Cooke C; Romanoff A; Choudhury N; Scanlon M; Kishore P; Sydney E; Masci J; Bakshi P; Pemmasani S; Davis NJ; Maru D
    BMJ Open; 2021 Nov; 11(11):e053158. PubMed ID: 34732494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study.
    Beaumont A; Durand C; Ledrans M; Schwoebel V; Noel H; Le Strat Y; Diulius D; Colombain L; Médus M; Gueudet P; Mouly D; Aumaître H
    BMJ Open; 2021 Nov; 11(11):e053201. PubMed ID: 34815286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Authors' response: Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.
    Reuter M; Rigó M; Formazin M; Liebers F; Latza U; Castell S; Jöckel KH; Greiser KH; Michels KB; Krause G; Albrecht S; Öztürk I; Kuss O; Berger K; Lampl BMJ; Leitzmann M; Zeeb H; Starke KR; Schipf S; Meinke-Franze C; Ahrens W; Seidler A; Klee B; Pischon T; Andreas Deckert AD; Schmidt B; Mikolajczyk R; Karch A; Bohn B; Brenner H; Holleczek B; Dragano N
    Scand J Work Environ Health; 2022 Sep; 48(7):588-590. PubMed ID: 36153787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clustering and longitudinal change in SARS-CoV-2 seroprevalence in school children in the canton of Zurich, Switzerland: prospective cohort study of 55 schools.
    Ulyte A; Radtke T; Abela IA; Haile SR; Berger C; Huber M; Schanz M; Schwarzmueller M; Trkola A; Fehr J; Puhan MA; Kriemler S
    BMJ; 2021 Mar; 372():n616. PubMed ID: 33731327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study.
    Bruggmann P; Senn O; Frei A; Puhan MA; Fehr J; Falcato L
    Swiss Med Wkly; 2022 Jan; 152():w30122. PubMed ID: 35019254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon.
    Essomba RG; Bayibeki AN; Lissom A; Ateba PT; Seni N; Fouda CAN; Mbitock SBD; Ebonda ND; Afana SD; Akame S; Tembu AA; Ngamaleu MR; Bimai BCB; Kabo O; Nguwoh PS; Ngounouh CT; Meka MCJ; Kengne M; Likeng JN; Kimessoukie EO; Nkoum BA; Assoumou MCO; Fokam J; Yap Boum II; Ambomo MS; Chadou MJP
    Influenza Other Respir Viruses; 2023 Nov; 17(11):e13222. PubMed ID: 37964992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid Spread of SARS-CoV-2 in a State Prison After Introduction by Newly Transferred Incarcerated Persons - Wisconsin, August 14-October 22, 2020.
    Hershow RB; Segaloff HE; Shockey AC; Florek KR; Murphy SK; DuBose W; Schaeffer TL; Powell Mph JA; Gayle K; Lambert L; Schwitters A; Clarke KEN; Westergaard R
    MMWR Morb Mortal Wkly Rep; 2021 Apr; 70(13):478-482. PubMed ID: 33793462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Seroprevalence in Employees of Four Essential Non-Health Care Sectors at Moderate/High Risk of Exposure to Coronavirus Infection: Data From the "First Wave".
    Belloni G; Dupraz J; Butty A; Pasquier J; Estoppey S; Bochud M; Gonseth-Nussle S; D'Acremont V
    J Occup Environ Med; 2023 Jan; 65(1):10-15. PubMed ID: 36094075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.
    Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP
    JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seroprevalence of and Risk Factors Associated With SARS-CoV-2 Infection in Health Care Workers During the Early COVID-19 Pandemic in Italy.
    Poletti P; Tirani M; Cereda D; Guzzetta G; Trentini F; Marziano V; Toso C; Piatti A; Piccarreta R; Melegaro A; Andreassi A; Gramegna M; Ajelli M; Merler S
    JAMA Netw Open; 2021 Jul; 4(7):e2115699. PubMed ID: 34228126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS CoV-2 seroprevalence and diagnostic accuracy during a COVID-19 outbreak in a major penitentiary complex in Brazil, June to July 2020.
    Gouvea-Reis FA; Soares da Silva DC; Borja LS; Dias PO; Percio J; Peterka C; de Oliveira J; Sodré G; Feres CM; Dos Santos W; Souza F; Passarella Teixeira AI; Cilião-Alves DC; Romero GAS; Ferreira Noronha E; Croda J; Haddad R; Ramalho WM; de Moraes C; Araújo WN
    Int J Prison Health; 2023 May; 19(2):143-156. PubMed ID: 38899623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
    Bergeri I; Whelan MG; Ware H; Subissi L; Nardone A; Lewis HC; Li Z; Ma X; Valenciano M; Cheng B; Al Ariqi L; Rashidian A; Okeibunor J; Azim T; Wijesinghe P; Le LV; Vaughan A; Pebody R; Vicari A; Yan T; Yanes-Lane M; Cao C; Clifton DA; Cheng MP; Papenburg J; Buckeridge D; Bobrovitz N; Arora RK; Van Kerkhove MD;
    PLoS Med; 2022 Nov; 19(11):e1004107. PubMed ID: 36355774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence and factors associated with SARS-CoV-2 infection among education workers after the first wave: the first cross-sectional study in Brazil.
    França PC; Silva PGB; Rocha JLC; Perdigão ACB; Oliveira NS; Araújo FMC; Fonseca MHG; Lima GRP; Almeida MM; Alencar CH; Oliveira WK; Cavalcanti LPG
    Rev Soc Bras Med Trop; 2022; 55():e06062021. PubMed ID: 35522813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust.
    Hodgson D; Colton H; Hornsby H; Brown R; Mckenzie J; Bradley KL; James C; Lindsey BB; Birch S; Marsh L; Wood S; Bayley M; Dickson G; James DC; Nicklin MJH; Sayers JR; Zafred D; Rowland-Jones SL; Kudesia G; Kucharski A; ; Darton TC; de Silva TI; Collini PJ
    medRxiv; 2021 Jul; ():. PubMed ID: 34268521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Saliva-Based Serological and Behavioral Analysis of SARS-CoV-2 Antibody Prevalence in Howard County, Maryland.
    Brown AC; Koshute PT; Cowley HP; Robinette MS; Gravelyn SR; Patel SV; Ju EY; Frommer CT; Zambidis AE; Schneider EJ; Zhao MY; Mugo BK; Clarke W; Kruczynski K; Pisanic N; Heaney CD; Colella TA
    Microbiol Spectr; 2023 Aug; 11(4):e0276522. PubMed ID: 37289070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low seropositivity for SARS-CoV-2 antibodies among healthcare workers after the first COVID-19 pandemic wave in Greece.
    Galanis P; Kaitelidou D; Prezerakos P; Kotsiopoulos I; Siskou O; Konstantakopoulou O; Hadjichristodoulou C; Tsiodras S
    Public Health; 2021 Sep; 198():223-229. PubMed ID: 34482100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroprevalence of COVID-19 in Oran: Cross-Sectional Study.
    Dali-Ali A; Derkaoui DK; Zina M; Oukebdane A
    Microbiol Spectr; 2023 Aug; 11(4):e0087623. PubMed ID: 37284756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.